GlassScriptPhysician profile
Martha E Lozano
NPI 1609845627
$17,146.08
in general payments reported to CMS, 2019-2025
57 companies · $2,468 in 2025
The $2,468 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,578 · 2020: $2,230 · 2021: $2,539 · 2022: $2,413 · 2023: $2,553 · 2024: $2,364 · 2025: $2,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,328 · Education: $57.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,327.54 |
| Education | $57.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,423.49 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $3,382.69 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,227.59 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Grifols USA, LLC | $1,130.18 | 2019-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $548.57 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $427.02 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Insmed, INC. | $402.38 | 2021-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $384.43 | 2019-2024 | Yupelri |
| Novo Nordisk INC | $339.09 | 2019-2025 | |
| Lilly USA, LLC | $323.17 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| United Therapeutics Corporation | $311.15 | 2022-2025 | Tyvaso, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $278.23 | 2021-2025 | Dupixent |
| Genzyme Corporation | $269.34 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $263.71 | 2019-2021 | |
| Genentech USA, INC. | $259.47 | 2019-2024 | Xolair |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $254.23 | 2020-2024 | Glassia |
| Philips North America LLC | $250.06 | 2019-2025 | Respiratory, Encore |
| Janssen Pharmaceuticals, INC | $190.30 | 2019-2022 | |
| Boston Scientific Corporation | $160.45 | 2019-2024 | Versacross Access Solution, Watchman Flx |
| Pfizer INC. | $152.82 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $151.14 | 2019-2021 | |
| Axsome Therapeutics, INC. | $145.51 | 2023-2025 | Sunosi |
| Abbvie INC. | $132.58 | 2021-2024 | |
| Radius Health, INC. | $130.68 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $123.98 | 2019-2025 | |
| Advanced Respiratory, INC | $118.74 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.21 | 2019-2024 | Xifaxan, Trulance |
| Baxter Healthcare | $107.86 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $99.68 | 2025 | Ohtuvayre |
| Amgen INC. | $98.48 | 2021-2025 | Repatha, Otezla, Tezspire |
| Gilead Sciences, INC. | $77.06 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.80 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $69.28 | 2021-2023 | Eliquis |
| Avadel Cns Pharmaceuticals, LLC | $68.32 | 2024-2025 | Lumryz |
| Mallinckrodt Hospital Products INC. | $62.48 | 2021-2025 | Acthar |
| Paratek Pharmaceuticals, INC. | $47.92 | 2022 | |
| Electromed, INC. | $43.93 | 2021-2025 | Smartvest |
| Medtronic, INC. | $41.88 | 2023 | Micra |
| Viatris Specialty LLC | $38.56 | 2025 | Yupelri |
| Phadia US INC. | $37.73 | 2021-2023 | Immunocap |
| Abbott Laboratories | $36.64 | 2020-2024 | |
| La Jolla Pharmaceutical Company | $34.12 | 2019-2020 | |
| Esperion Therapeutics, INC. | $32.19 | 2020 | |
| Daiichi Sankyo INC. | $31.73 | 2019 | |
| Acadia Pharmaceuticals INC | $30.85 | 2025 | Daybue |
| Shire North American Group INC | $26.22 | 2019 | |
| Medtronic Vascular, INC. | $25.89 | 2019 | |
| Recordati_rare_diseases_inc. | $22.22 | 2025 | Isturisa |
| Otsuka America Pharmaceutical, INC. | $21.88 | 2024 | Rexulti |
| Inogen, INC. | $17.75 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Tactile Systems Technology INC | $16.61 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.16 | 2021 | |
| Seqirus USA INC | $15.07 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.85 | 2023 | Horizant |
| 3b Medical, INC. | $13.82 | 2025 | Luna |
| Allergan, INC. | $13.38 | 2020 | |
| Sanofi Pasteur INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Lozano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.